JP2002512954A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002512954A5 JP2002512954A5 JP2000545520A JP2000545520A JP2002512954A5 JP 2002512954 A5 JP2002512954 A5 JP 2002512954A5 JP 2000545520 A JP2000545520 A JP 2000545520A JP 2000545520 A JP2000545520 A JP 2000545520A JP 2002512954 A5 JP2002512954 A5 JP 2002512954A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- disease
- alkyl
- related disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- -1 —SR Chemical group 0.000 description 17
- 201000010099 disease Diseases 0.000 description 16
- 125000000217 alkyl group Chemical group 0.000 description 10
- 210000003470 mitochondria Anatomy 0.000 description 7
- 230000002438 mitochondrial effect Effects 0.000 description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- 125000003545 alkoxy group Chemical group 0.000 description 4
- 125000003710 aryl alkyl group Chemical group 0.000 description 4
- 125000001475 halogen functional group Chemical group 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 4
- 125000005647 linker group Chemical group 0.000 description 4
- 125000001624 naphthyl group Chemical group 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 201000000915 Chronic Progressive External Ophthalmoplegia Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 206010011878 Deafness Diseases 0.000 description 2
- 208000014413 Maternally-inherited diabetes and deafness Diseases 0.000 description 2
- 208000021642 Muscular disease Diseases 0.000 description 2
- 206010036802 Progressive external ophthalmoplegia Diseases 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 231100000895 deafness Toxicity 0.000 description 2
- 208000016354 hearing loss disease Diseases 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 125000005809 3,4,5-trimethoxyphenyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 1
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 208000014094 Dystonic disease Diseases 0.000 description 1
- 208000024658 Epilepsy syndrome Diseases 0.000 description 1
- 208000002877 Epileptic Syndromes Diseases 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100022745 Laminin subunit alpha-2 Human genes 0.000 description 1
- 206010058799 Mitochondrial encephalomyopathy Diseases 0.000 description 1
- 208000002033 Myoclonus Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 1
- 201000010802 Wolfram syndrome Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 201000006815 congenital muscular dystrophy Diseases 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 201000010064 diabetes insipidus Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 208000014188 hereditary optic neuropathy Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 206010030875 ophthalmoplegia Diseases 0.000 description 1
- 208000001749 optic atrophy Diseases 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 210000002807 slow-twitch muscle fiber Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8299898P | 1998-04-24 | 1998-04-24 | |
| US60/082,998 | 1998-04-24 | ||
| PCT/US1999/008880 WO1999055321A1 (en) | 1998-04-24 | 1999-04-23 | Compounds and methods for treating mitochondria-associated diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002512954A JP2002512954A (ja) | 2002-05-08 |
| JP2002512954A5 true JP2002512954A5 (https=) | 2006-06-22 |
Family
ID=22174789
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000545520A Pending JP2002512954A (ja) | 1998-04-24 | 1999-04-23 | ミトコンドリア関連疾患を処置するための化合物および方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US6268398B1 (https=) |
| EP (1) | EP1071414A1 (https=) |
| JP (1) | JP2002512954A (https=) |
| AU (1) | AU3965699A (https=) |
| CA (1) | CA2329709A1 (https=) |
| WO (1) | WO1999055321A1 (https=) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU767526B2 (en) | 1999-04-26 | 2003-11-13 | Gmp Vision Solutions, Inc. | Trabeculotomy device and method for treating glaucoma |
| US20050119601A9 (en) * | 1999-04-26 | 2005-06-02 | Lynch Mary G. | Shunt device and method for treating glaucoma |
| US7005274B1 (en) * | 1999-09-15 | 2006-02-28 | Migenix Corp. | Methods and compositions for diagnosing and treating arthritic disorders and regulating bone mass |
| US7867186B2 (en) | 2002-04-08 | 2011-01-11 | Glaukos Corporation | Devices and methods for treatment of ocular disorders |
| US20020143284A1 (en) * | 2001-04-03 | 2002-10-03 | Hosheng Tu | Drug-releasing trabecular implant for glaucoma treatment |
| US7708711B2 (en) | 2000-04-14 | 2010-05-04 | Glaukos Corporation | Ocular implant with therapeutic agents and methods thereof |
| US6638239B1 (en) | 2000-04-14 | 2003-10-28 | Glaukos Corporation | Apparatus and method for treating glaucoma |
| US20030060752A1 (en) * | 2000-04-14 | 2003-03-27 | Olav Bergheim | Glaucoma device and methods thereof |
| US20080145351A1 (en) * | 2000-04-20 | 2008-06-19 | The Research Foundation Of State University Of New York | Memory influencing protein |
| US7928070B2 (en) * | 2000-04-20 | 2011-04-19 | The Research Foundation Of State University Of Ny | Memory enhancing protein |
| HUP0004154A3 (en) * | 2000-10-26 | 2003-11-28 | Sanofi Synthelabo | Process for the preparation of 1,5-disubstituted-3-amino-1,2,4-triazole derivatives |
| US20020102614A1 (en) * | 2000-11-17 | 2002-08-01 | Davis Roger J. | Use of ZPR1 as a molecular probe for spinal muscular atrophy |
| WO2002043559A2 (en) * | 2000-11-30 | 2002-06-06 | Rambam Medical Center Funds For Medical Research Development Of Infrastructure And Health Services | Methods and kits for diagnosis of schizophrenia |
| US6552076B2 (en) | 2000-12-15 | 2003-04-22 | Mitokor | Compounds for altering mitochondrial function and cellular responses |
| US6548531B2 (en) * | 2001-02-09 | 2003-04-15 | Hoffmann-La Roche Inc. | Method for cancer therapy |
| US6981958B1 (en) | 2001-05-02 | 2006-01-03 | Glaukos Corporation | Implant with pressure sensor for glaucoma treatment |
| AU2002258754B2 (en) | 2001-04-07 | 2006-08-17 | Glaukos Corporation | Glaucoma stent and methods thereof for glaucoma treatment |
| US7431710B2 (en) | 2002-04-08 | 2008-10-07 | Glaukos Corporation | Ocular implants with anchors and methods thereof |
| US6666841B2 (en) | 2001-05-02 | 2003-12-23 | Glaukos Corporation | Bifurcatable trabecular shunt for glaucoma treatment |
| US7488303B1 (en) | 2002-09-21 | 2009-02-10 | Glaukos Corporation | Ocular implant with anchor and multiple openings |
| US7678065B2 (en) | 2001-05-02 | 2010-03-16 | Glaukos Corporation | Implant with intraocular pressure sensor for glaucoma treatment |
| WO2002089699A2 (en) | 2001-05-03 | 2002-11-14 | Glaukos Corporation | Medical device and methods of use for glaucoma treatment |
| US7331984B2 (en) | 2001-08-28 | 2008-02-19 | Glaukos Corporation | Glaucoma stent for treating glaucoma and methods of use |
| CA2356540A1 (en) * | 2001-08-30 | 2003-02-28 | Emory University | Expressed dna sequences involved in mitochondrial functions |
| JP2005515757A (ja) * | 2001-08-30 | 2005-06-02 | エモリー・ユニバーシティ | ミトコンドリア生物学発現アレイ |
| US20050123913A1 (en) * | 2001-08-30 | 2005-06-09 | Emory University | Human mitochondrial dna polymorphisms, haplogroups, associations with physiological conditions, and genotyping arrays |
| US20030097151A1 (en) * | 2001-10-25 | 2003-05-22 | Smedley Gregory T. | Apparatus and mitochondrial treatment for glaucoma |
| US7186232B1 (en) | 2002-03-07 | 2007-03-06 | Glaukoa Corporation | Fluid infusion methods for glaucoma treatment |
| US7951155B2 (en) | 2002-03-15 | 2011-05-31 | Glaukos Corporation | Combined treatment for cataract and glaucoma treatment |
| US9301875B2 (en) | 2002-04-08 | 2016-04-05 | Glaukos Corporation | Ocular disorder treatment implants with multiple opening |
| CN101440124B (zh) * | 2003-02-04 | 2012-07-18 | 科内尔研究基金会 | 用于防止线粒体通透性改变的方法 |
| SI2656854T1 (sl) * | 2003-02-04 | 2015-09-30 | Cornell Research Foundation, Inc. | Uporabe aromatsko-kationskega peptida |
| JP4879020B2 (ja) * | 2003-05-01 | 2012-02-15 | コーネル リサーチ ファウンデイション インコーポレイテッド | 細胞に分子を送達する方法及び担体複合体 |
| RU2237658C1 (ru) * | 2003-07-10 | 2004-10-10 | Общество с ограниченной ответственностью "Международный институт эколого-технологических проблем" | Гидрохлорид п-гуанидиносалицилата натрия |
| CA2851972C (en) * | 2004-01-23 | 2015-06-23 | Cornell Research Foundation, Inc. | Methods for reducing oxidative damage |
| FI121915B (fi) * | 2004-02-06 | 2011-06-15 | Neurofood Ab Oy | Koostumus psoriasiksen hoitoon |
| CA2947335A1 (en) | 2005-09-16 | 2007-03-29 | Cornell Research Foundation, Inc. | Methods for reducing cd36 expression |
| US20070293807A1 (en) * | 2006-05-01 | 2007-12-20 | Lynch Mary G | Dual drainage pathway shunt device and method for treating glaucoma |
| WO2008061043A2 (en) | 2006-11-10 | 2008-05-22 | Glaukos Corporation | Uveoscleral shunt and methods for implanting same |
| CA2674296C (en) * | 2007-01-04 | 2015-11-24 | Debiopharm Sa | Non-immunosuppressive cyclosporin for treatment of ullrich congenital muscular dystrophy |
| GB0800383D0 (en) * | 2008-01-10 | 2008-02-20 | Univ Strathclyde | Weight reducing compounds |
| EP3103467A1 (en) | 2008-02-07 | 2016-12-14 | Cornell University | Methods for preventing or treating insulin resistance |
| DK2262520T3 (en) | 2008-02-26 | 2017-08-07 | Univ Cornell | COMPOSITIONS FOR PREVENTION AND TREATMENT OF Kidney Injury |
| GB2466622A (en) * | 2008-12-23 | 2010-06-30 | Trinity College Dublin | Alpha2-Adrenoceptor Ligands |
| EP3563862B1 (en) | 2009-03-20 | 2021-05-05 | The General Hospital Corporation d/b/a Massachusetts General Hospital | D-arg-2'6'-dimethyltyrosine-lys-phe-nh2 for use in the prevention of secondary complications of burn injuries |
| CA3186189A1 (en) | 2009-05-18 | 2010-11-25 | Dose Medical Corporation | Drug eluting ocular implant |
| US12478503B2 (en) | 2009-05-18 | 2025-11-25 | Glaukos Corporation | Implants with controlled drug delivery features and methods of using same |
| US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
| CN105031605A (zh) * | 2009-08-12 | 2015-11-11 | 康奈尔大学 | 预防或治疗代谢综合症的方法 |
| PL2470191T3 (pl) | 2009-08-24 | 2014-09-30 | Stealth Peptides Int Inc | Sposoby i kompozycje do profilaktyki lub leczenia stanów okulistycznych |
| EP2485749A4 (en) * | 2009-10-05 | 2013-07-24 | Univ Cornell | METHOD FOR THE PREVENTION AND TREATMENT OF HEART FAILURE |
| US9668915B2 (en) | 2010-11-24 | 2017-06-06 | Dose Medical Corporation | Drug eluting ocular implant |
| EP3659495B1 (en) | 2011-09-13 | 2022-12-14 | Dose Medical Corporation | Intraocular physiological sensor |
| EP2822548B1 (en) * | 2012-02-08 | 2019-04-24 | University of Virginia Patent Foundation | Long chain base sphingosine kinase inhibitors |
| US9730638B2 (en) | 2013-03-13 | 2017-08-15 | Glaukos Corporation | Intraocular physiological sensor |
| US9592151B2 (en) | 2013-03-15 | 2017-03-14 | Glaukos Corporation | Systems and methods for delivering an ocular implant to the suprachoroidal space within an eye |
| US11925578B2 (en) | 2015-09-02 | 2024-03-12 | Glaukos Corporation | Drug delivery implants with bi-directional delivery capacity |
| WO2017053885A1 (en) | 2015-09-25 | 2017-03-30 | Glaukos Corporation | Punctal implants with controlled drug delivery features and methods of using same |
| EP3442479B1 (en) | 2016-04-20 | 2026-03-04 | Glaukos Corporation | Bioresorbable ocular drug delivery device |
| EP3749697A4 (en) | 2018-02-05 | 2021-11-03 | Bio-Rad Laboratories, Inc. | CHROMATOGRAPHY RESIN WITH LIGAND MIXED MODE ANIONIC / HYDROPHOBIC EXCHANGE |
| CN115811995B (zh) | 2020-05-15 | 2023-11-03 | 视觉流公司 | 用于在哺乳动物眼睛的常规房水流出通路中植入的方法和设备 |
| CN114195724A (zh) * | 2021-12-16 | 2022-03-18 | 深圳市祥根生物医药有限公司 | 一种酒石酸溴莫尼定杂质e的制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3541218A (en) | 1969-06-18 | 1970-11-17 | Lilly Co Eli | Omicron-fluorobenzylaminoguanidine for diabetes |
| US4014934A (en) * | 1974-04-15 | 1977-03-29 | Armour Pharmaceutical Company | Substituted 4'-hydroxyphenyl guanidines and methods of using the same |
| US5847006A (en) | 1991-02-08 | 1998-12-08 | Cambridge Neuroscience, Inc. | Therapeutic guanidines |
| DE69230220T2 (de) | 1991-02-08 | 2000-06-21 | Cambridge Neuroscience Research, Inc. | Substituierte guanidine und derivate hiervon als modulatoren der freisetzung von neurotransmittern und neue methode zur identifizierung von inhibitoren der neurotransmitter-freisetzung |
| JPH06510760A (ja) * | 1991-08-27 | 1994-12-01 | ジ・アップジョン・カンパニー | 代謝障害および代謝の治療法 |
| GB9511757D0 (en) * | 1995-05-19 | 1995-08-02 | Univ Strathclyde | Agents for reducing weight |
| HU9502843D0 (en) | 1995-09-29 | 1995-11-28 | Livigene Ltd | Pharmaceutical composition |
| JPH10195037A (ja) * | 1996-02-15 | 1998-07-28 | Tanabe Seiyaku Co Ltd | フェノール誘導体 |
| CA2197364A1 (en) * | 1996-02-15 | 1997-08-16 | Toshikazu Suzuki | Phenol compound and process for preparing the same |
| WO1997045108A1 (en) * | 1996-05-30 | 1997-12-04 | Children's Hospital Medical Center | Guanidino derivatives as inhibitors of the cytotoxic effect of peroxynitrite |
-
1999
- 1999-04-23 JP JP2000545520A patent/JP2002512954A/ja active Pending
- 1999-04-23 EP EP99922721A patent/EP1071414A1/en not_active Withdrawn
- 1999-04-23 US US09/299,044 patent/US6268398B1/en not_active Expired - Fee Related
- 1999-04-23 CA CA002329709A patent/CA2329709A1/en not_active Abandoned
- 1999-04-23 WO PCT/US1999/008880 patent/WO1999055321A1/en not_active Ceased
- 1999-04-23 AU AU39656/99A patent/AU3965699A/en not_active Abandoned
-
2001
- 2001-06-05 US US09/875,450 patent/US20020052409A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002512954A5 (https=) | ||
| CA2440037A1 (en) | Benzimidazole derivatives for modulating the rage receptor | |
| WO1998056788B1 (en) | Imidazolyl-cyclic acetals | |
| JP2004520292A5 (https=) | ||
| JPH04982B2 (https=) | ||
| JP2003509349A5 (https=) | ||
| JP2005504736A5 (https=) | ||
| FI3856341T3 (fi) | (s)-1-(4-fluorifenyyli)-1-(2-(4-(6-(1-metyyli-1h-pyratsol-4-yyli)pyrrolo[2,1-f][1,2,4]triatsin-4-yyli)piperatsinyyli)pyrimidin-5-yyli)etaani-1-amiinin kidemuotoja ja valmistusmenetelmiä | |
| JP2007530601A5 (https=) | ||
| EP1796727A2 (en) | Method for the treatment of polycystic kidney disease | |
| EP0575749A2 (en) | Use of potassium-channel activators for the manufacture of a medicament for the treatment of gastrointertinal ulcers | |
| CA2547347A1 (en) | Diazaindole-dicarbonyl-piperazinyl antiviral agents | |
| CA2522738A1 (en) | Compounds for the treatment of metabolic disorders | |
| JP2004521150A5 (https=) | ||
| RU2004103475A (ru) | Производные арил-или гетероарилазолилкарбинолов для лечения недержания мочи | |
| GB2259013A (en) | Neuroprotective use of CCK antagonists | |
| JPWO2001036402A1 (ja) | 新規な２−（ｎ−シアノイミノ）チアゾリジン−４−オン誘導体 | |
| CN119233823A (zh) | 硼化合物治疗非结核分枝杆菌感染的方法和用途及用于治疗相同疾病的药物组合物 | |
| US4145441A (en) | Sympathomimetic amines exhibiting anti-hemorrhoidal activity | |
| CA2423628A1 (en) | Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing them | |
| DE10150517A1 (de) | Verwendung von Phosphodiesterase IV-Inhibitoren | |
| MX2025008544A (es) | Derivados de 3-(2-(dimetilamino)etil)-1h-indol-4-ilo | |
| WO2004052350A3 (en) | Method of treating movement disorders using barbituric acid derivatives | |
| WO1996039391B1 (en) | Styryl benzimidazole derivatives as inhibitors of smooth muscle cell proliferation | |
| JP2007518673A5 (https=) |